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Abstract
Lipopolysaccharide (LPS), the Gram-negative bacterial outer membrane glycolipid, induces sepsis through its interaction
with myeloid differentiation protein-2 (MD-2) and Toll-like receptor 4 (TLR4). To block interaction between LPS/MD-2
complex and TLR4, we designed and generated soluble fusion proteins capable of binding MD-2, dubbed TLR4 decoy
receptor (TOY) using ‘the Hybrid leucine-rich repeats (LRR) technique’. TOY contains the MD-2 binding ectodomain of TLR4,
the LRR motif of hagfish variable lymphocyte receptor (VLR), and the Fc domain of IgG1 to make it soluble, productive, and
functional. TOY exhibited strong binding to MD-2, but not to the extracellular matrix (ECM), resulting in a favorable
pharmacokinetic profile in vivo. TOY significantly extended the lifespan, when administered in either preventive or
therapeutic manners, in both the LPS- and cecal ligation/puncture-induced sepsis models in mice. TOY markedly attenuated
LPS-triggered NF-kB activation, secretion of proinflammatory cytokines, and thrombus formation in multiple organs. Taken
together, the targeting strategy for sequestration of LPS/MD-2 complex using the decoy receptor TOY is effective in treating
LPS- and bacteria-induced sepsis; furthermore, the strategy used in TOY development can be applied to the generation of
other novel decoy receptor proteins.
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Introduction
Sepsis caused by Gram-negative bacterial infection is a life-
threatening disease characterized by profound inflammatory
responses, multi-organ dysfunction with marked thrombus forma-
tion, and a high mortality rate (,60%) [1]. Lipopolysaccharide
(LPS), the Gram-negative bacterial outer membrane glycolipid,
induces sepsis through its interaction with LPS-binding protein
(LBP) or CD14 prior to subsequent formation of a complex with
myeloid differentiation protein-2 (MD-2) and Toll-like receptor 4
(TLR4) [2–12].
Human TLR4 contains a 608-residue extracellular domain, a
single transmembrane domain, and a 187-residue intracellular
domain [13]. Crystal structural analysis has shown that TLR4
adopts the characteristic horseshoe-like shape of the LRR
superfamily, with N-terminal (amino acids 27–202), central (amino
acids 203–348), and C-terminal (amino acids 349–582) domains
[14,15]. MD-2 binds to the concave surface of the N-terminal and
central domains of TLR4 [14]. In addition to TLR4-bound MD-
2, the MD-2 protein is also secreted into the extracellular milieu in
a soluble form, which is present in circulating blood [16,17]. MD-
2 has a b-cup fold structure that forms a hydrophobic pocket for
LPS binding [14,18]. Binding of the LPS/MD-2 complex
to TLR4 causes TLR4 dimerization, and results in the activation
of NF-kB leading to acute and severe inflammation and sepsis
[7–9,19].
In this regard, blocking TLR4 signaling activation using a decoy
receptor could be an effective way to prevent LPS- or Gram-
negative bacteria-induced sepsis if applied prior to or after
challenge. Although two research groups have tried to generate
the extracellular domain of TLR4 protein as a decoy receptor for
MD-2 [17,20], it proved difficult to generate a substantial amount
of the protein because it is insoluble, its production rate is
extremely low, and it is hard to purify due to its intrinsic
biochemical properties. Therefore, the trial of blocking TLR4
using a decoy receptor in preventing sepsis under in vivo conditions
has not been achieved until now. To overcome these problems, we
recently developed a novel method, ‘the Hybrid LRR Technique
[14]’, to generate a massive amount of soluble extracellular
domains of TLR4 protein. Variable lymphocyte receptors (VLRs)
are a new type of immune receptors in jawless fish. These
receptors resemble the adaptive immune receptors in jawed
vertebrates. VLRs and TLRs commonly contain the LRR domain
in the extracellular fragment, which is composed of a signal
sequence, an N-terminal cap (LRRNT), several LRR modules,
and a C-terminal cap (LRRCT) [14,21]. Therefore, stable TLR4-
VLR hybrid proteins can be generated in large amounts without
any loss of the intrinsic structural integrity of TLR4 by replacing
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termed TV3 and TV8 [14]. The TV3 and TV8 proteins are able
to complex with MD-2 and Eritoran (a synthetic LPS antagonist)
[22]. By fusion of the Fc domain of IgG1 to TV3 and TV8, we
were able to generate dimeric TLR4 decoy receptor TOY, which
is effective in treating LPS- and bacteria-induced sepsis.
Results and Discussion
We fused human IgG-Fc to the carboxy-terminal portion of
TV3 and TV8, and named the resulting products TLR4 decoy
receptor-3 and -8 (TOY3 and TOY8) (Figure 1A). As a control,
we also produced a fusion of IgG-Fc to the TLR4 full-length
ectodomain (TFE; Figure 1A). We used computer modeling
based on crystal structures to illustrate the potential structures of
the three constructs (Figure 1B). We were able to produce the
TFE, TOY3, and TOY8 proteins in CHO cells at rates of 0.1,
,20, and ,15 mg/L. The production rates of TOY3 and TOY8
are currently amplified by the methotrexate selection process [23].
The purified TFE, TOY3, and TOY8 under reducing conditions
revealed predominantly single bands of the expected molecular
masses of ,110, ,65 and, ,105 kDa, respectively (Figure 1C).
Under non-reducing conditions, the recombinant proteins were
present as disulfide-linked dimers due to the presence of the Fc
domain (Figure 1C). In vitro binding analysis revealed that TFE,
TOY3, or TOY8 could interact not only with MD-2 but also with
LPS/MD-2 complex (Figure 2 and Figure S1). Surface plasmon
resonance analyses revealed that all three proteins directly
interacted with MD-2, and the KD of TFE, TOY3, and TOY8
binding to MD-2 was ,81, ,76, and ,56 nM (Figure 2C).
Thus, the VLR component in TOY did not substantially alter the
binding affinity for MD-2. In vitro analyses demonstrated that both
Figure 1. Structures of TFE and TOY constructs. (A) Schematic diagrams of the constructs showing the relative sizes of the human TLR4
ectodomain (TLR4), VLRB.61 fragment (VLR) of hagfish, and human IgG-Fc (Fc). Numbers indicate amino acids of the parental proteins. (B) Crystal
structures based on computer modeling. The domains depicted are TLR4 (red), VLR (yellow), and Fc (blue). (C) Each 2 mg of reduced (R) and
nonreduced (NR) proteins was separated by SDS-PAGE and stained with Coomassie blue. Molecular masses (kDa) are indicated at left.
doi:10.1371/journal.pone.0007403.g001
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tion in primary cultured lymphatic endothelial cells (Figure 3A
and 3B) and also diminished LPS-induced TNF-a secretion in
macrophages (Figure 3C).
The isoelectric point (pI) of a recombinant protein affects its
bioavailability and pharmacokinetics in vivo. High-pI proteins
suffer from poor bioavailability because they adhere nonspecifi-
cally to the negatively charged proteoglycans of the extracellular
matrix (ECM). While the theoretical pI values of TFE, TOY3, and
TOY8 are 5.7, 11.8, and 6.0, their actual pI values are 5.0, 5.2,
and 5.5, possibly due to abundant N-linked glycosylation
(Figure 4). Indeed, the ECM binding assay demonstrated that
TFE, TOY3, and TOY8 had minimal binding to ECM, whereas
Flt1-Fc (pI 9.1) bound strongly to ECM (Figure 5A). To examine
the in vivo pharmacokinetic profiles of the proteins, we performed a
single intraperitoneal injection (5 mg/kg) of TOY3, TOY8, or
Flt1-Fc recombinant protein into mice. TOY3 and TOY8 proteins
were rapidly absorbed from the peritoneal cavity into systemic
circulation. The proteins reached maximum levels in blood at
1,2 hr after injection, and their half-lives (t1/2) were ,2 days
(Figure 5B). In mice (n=4), TOY3 had a maximal concentration
(Cmax) of 7.0060.13 mg/ml and AUC (total ‘‘area under the curve
of concentration’’) of 20.5060.96, TOY8 had a Cmax of
7.0360.85 mg/ml and AUC of 18.2761.24, and Flt1-Fc had
Cmax of 5.2860.49 mg/ml and AUC of 9.9660.84. Thus, the
pharmacokinetic profiles of the proteins were correlated to their in
vitro ECM adhesion properties. TOY3 and TOY8 have relatively
high bioavailability and excellent pharmacokinetic profiles in vivo,
raising the possibility that TOY could block LPS/MD-2/TLR4
signaling in vivo by providing a decoy for TLR4.
To explore whether the TOY proteins could ameliorate sepsis in
vivo, eight experiments were performed. For the first and second
experiment, 20 mg/kg of TOY3 or TOY8 was given to mice at
30 min prior to or at 1 hr after administration of LPS (15 mg/kg)
(‘preventive model’ or ‘therapeutic model’). Both TOY3- and
TOY8-treated mice had an extended lifespan compared to Fc-
treated mice (50% survival: ,58 hr versus ,22 hr, P,0.001 in
the preventive model; ,49 hr versus ,22 hr, P,0.001 in the
therapeutic model) (Figure 6A and 6B). For the third and fourth
experiment, 20 mg/kg of TOY3 or TOY8 was given to the mice
at 1 hr prior to or at 1 hr after generation of acute peritonitis by
cecal ligation and puncture (CLP) (‘preventive model’ or
‘therapeutic model’). Both TOY3- and TOY8-treated mice had
a prolonged lifespan compared to Fc-treated mice (50% survival:
Figure 2. In vitro binding analysis reveals that LPS binds to TFE, TOY3, or TOY8 through MD-2 and BIAcore analysis of interaction
between TFE, TOY3, or TOY8 and MD-2. (A) 200 ng of Fc, TFE, TOY3, or TOY8 were coated onto 96-well plates. FITC-labeled LPS (10 mg/ml) was
incubated in the presence or absence of MD-2 (1 mg/ml) in each indicated well for 2 hr. The fluorescence signal was measured by IVIS imaging. (B)
Fluorescence was quantified and expressed as radiance (photon/sec/cm
2/steradian). Bars represent means 6 S.D. (n=4). *, P,0.05 versus Fc+hMD-
2+FITC-LPS (1). The x-axis numbering represents the number of each well in (A). (C) Sensorgrams for the association and dissociation of MD-2 on
immobilized TFE, TOY3, or TOY8. One microgram of TFE, TOY3, or TOY8 was immobilized on a Sensor Chip CM5 (BIAcore) using N-hydroxysuccinimide
(NHS) and 1-ethyl-3(3-dimethylaminopropyl) carbodiimide (EDC) amine coupling reagent at approximately 2,000 resonance units (RU). As a control,
BSA protein was immobilized on another portion of the same chip. Recombinant MD-2 proteins were then applied onto the immobilized TFE, TOY3,
or TOY8 surfaces, and the amount captured was recorded in sensorgrams as RU. All samples were in running buffer to minimize bulk effects. The
kinetic parameters of the binding interactions were calculated from the sensorgrams by nonlinear curve fitting using BIAEVALUATION software
(BIAcore). RU represents resonance units.
doi:10.1371/journal.pone.0007403.g002
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versus ,32 hr, P,0.001 in the therapeutic model) (Figure 6C
and 6D). Thus, surprisingly, both TOY3 and TOY8 showed
prominent preventive and therapeutic effects in the LPS- and
CLP-induced sepsis models. For the fifth experiment, 20 mg/kg of
TOY3 was given to the mice at 1 hr and 12 hr after
administration of LPS (15 mg/kg) (‘repeated treatment to
therapeutic model’). The TOY3-treated mice had a markedly
extended lifespan compared to Fc-treated mice (50% survival:
,60 hr versus ,26 hr, P,0.001), and the 40% of TOY3-treated
mice were completely rescued to live (Figure 6E). For the sixth
experiment, 20 mg/kg of TOY3 was given to the mice at 1 hr and
12 hr after generation of CLP (‘repeated treatment to therapeutic
model’). The repeated administration of TOY3 led to a dramatic
increase in survival up to 96 hr after CLP (TOY3 versus Fc; 60%
versus 0%, P,0.001) (Figure 6F). Thus, the repeated treatments
with TOY3 markedly attenuated lethality in both the LPS- and
CLP-induced sepsis models compared to the single treatment of
TOY3 (50% survival: ,60 hr versus ,50 hr, P,0.01 in the LPS-
induced sepsis model; 70% survival: ,60 hr versus ,50 hr,
P,0.01 in the CLP-induced sepsis model). For the seventh and
eighth experiments, 20 mg/kg of TOY3 was given to mice at 6 hr
and 12 hr after administration of LPS (15 mg/kg) or the CLP
procedure (‘clinically relevant model’). These repeated adminis-
trations of TOY3 also significantly improved survival compared to
the controls in both the LPS- and CLP-induced sepsis models
(50% survival: ,69 hr versus ,21 hr, P,0.001 in the LPS-
induced sepsis model; ,84 hr versus ,32 hr, P,0.001 in the
CLP-induced sepsis model) (Figure 7A and 7B). These repeated
treatments with TOY3 markedly attenuated lethality in both the
LPS- and CLP-induced sepsis models compared to the single
treatment of TOY3 (50% survival: ,70 hr versus ,50 hr, P,0.01
in the LPS-induced sepsis model; ,84 hr versus ,60 hr, P,0.01
in the CLP-induced sepsis model). Therefore, repeated treatments
with TOY3 could ameliorate sepsis even in a more clinically
relevant situation.
Figure 3. Pre-incubation of TFE, TOY3, and TOY8 markedly attenuates LPS-induced NF-kB activation in primary cultured
lymphatic endothelial cells and TNF-a secretion in peritoneal macrophages. LEC (primary lymphatic microvascular endothelial cells
derived from human adult dermis) were purchased from Cambrex Inc. (East Rutherford, NJ) and maintained in endothelial cell basal medium-2
with growth supplements (EBM-2 MV). Passage 4–6 LEC were incu b a t e di nE B M - 2M Vc o n t a i n i n g1%F B Sf o r8h ra n dt h e nw i t h1mg/ml of Fc, TFE,
TOY3, or TOY8 for 15 min, and then the LEC were treated with LPS (500 ng/ml) for 30 min. (A) For determination of NF-kB activation, nuclear
translocalization of p65 (a subunit of NF-kB) was analyzed by immunostaining (green). Nuclei were counterstained with DAPI (blue). Arrows
indicate nuclear translocalization of p65. Scale bars, 100 mm. (B) Cells positive for p65 intranuclear staining (white arrows) were counted among
100 cells arbitrarily chosen in 4 different regions, and the values presented as a percentage of the total cell number. Bars represent means 6 S.D.
(n=4).*,P,0.05 versus Fc. (C) Primary cultured macrophages from mouse peritoneal cavity were pre-treated with 1.0 mg/ml of Fc, TOY3, or TOY8
for 30 min, and then were treated with LPS (100 ng/ml) for 4 hr. Culture media were sampled, and levels of TNF-a were measured. Bars represent
means 6 S.D. (n=5).*,P,0.05 versus Fc.
doi:10.1371/journal.pone.0007403.g003
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secretions of proinflammatory cytokines and thrombus formation
in blood vessels, and both effects are brought through activation of
NF-kB [2,24]. To determine whether TOY attenuates NF-kB
activation and subsequent secretion of proinflammatory cytokines
and thrombus formation, we monitored these parameters in the
LPS ‘therapeutic model’ using NFkB-RE-luc [25] and wild-type
mice. At 24 hr after LPS (1 mg/kg) administration, the lumines-
cence signal examined by IVIS imaging system was markedly up-
regulated in most regions of NFkB-RE-luc mice, whereas the signal
was barely detected in PBS-treated NFkB-RE-luc mice (Figure 8A
and 8B). Both TOY3 and TOY8 significantly attenuated the
LPS-induced up-regulation of the signal in the NFkB-RE-luc mice
(Figure 8A and 8B). At 6 or 24 hr after LPS (7.5 mg/kg)
Figure 4. Isoelectric focusing and glycosylation analysis of TFE, TOY3, and TOY8. (A)2 0mg of the indicated protein was loaded on an
IsoGel Agarose IEF Plate and run at 50 mA constant current for 3 hr. The gels were stained with Coomassie blue. Each bracket marks the pI range of
the indicated protein. Reference pI values are indicated by the standard marker proteins (SMP). (B)2mg of the indicated protein was digested with O-
glycosidase (O) and PNGase F (N) and was separated by SDS-PAGE and stained with Coomassie blue. Each undigested protein was used as control (U).
Molecular masses (kDa) are indicated at left.
doi:10.1371/journal.pone.0007403.g004
Figure 5. TOY3 and TOY8 have low binding affinity to ECM in vitro and display excellent pharmacokinetic profiles in vivo. (A) ELISA
analysis depicting the binding affinity for different concentrations (0.3, 1, 3, 10, 30 nM) of each indicated protein to ECM. Values are given as means 6
S.D. (n=4). *, P,0.05 versus Fc. (B) Pharmacokinetic profiles. The indicated protein (5 mg/kg) was injected intraperitoneally into C57BL/6 mice. Then
blood samples were taken from the tail vein at 1, 2, 4, 8, 12, 24, 48, 96, and 144 hrs, and serum levels of the proteins were measured by ELISA. Values
are given as means 6 S.D. (n=4). *, P,0.05 versus Fc.
doi:10.1371/journal.pone.0007403.g005
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thrombi in the blood vessels of liver, adrenal cortex, lung, and
brain were profoundly increased in the wild-type mice (Figure 8C
and 8D). The mice treated with either TOY3 or TOY8 had
markedly reduced levels of TNF-a, IL-1b, and IL-6 in plasma
(Figure 8C), and fewer thrombi in the blood vessels (Figure 8D).
Thus, TOY attenuated LPS-induced NF-kB activation, which
increases the secretion of proinflammatory cytokines and results in
thrombus formation in multiple organs.
In this study, we report for the first time the production of a
TLR4 decoy receptor, TOY, which can be easily generated in
large amounts. We also show for the first time that a modified
decoy receptor of TLR4, TOY, is effective not only for prevention,
but also for treatment of LPS- and bacteria-induced sepsis in mice.
Because TOY would be used only once or twice during treatment
of a life-threatening septic condition, the immune reaction against
to TOY is not being considered. TOY3 and TOY8 produced
almost identical effects in preventing sepsis; since TOY3 bears
only the ‘A patch’ of the TLR4, this result implies that the ‘A
patch’ of the TLR4 ectodomain is sufficient for MD-2 binding in
vivo [14]. These findings give us additional structural information
in TLR4 biology which shows that further application of TLR4
Figure 6. TOY attenuates lethality in two sepsis mouse models and is effective in both prophylactic and therapeutic treatments.
(A–D) 20 mg/kg of Fc, TOY3, or TOY8 was given intraperitoneally to mice 30 min before (A) or 1 hr after (B) intraperitoneal administration of LPS
(15 mg/kg). The protein is given 1 hr before (C) or 1 hr after (D) generation of CLP. (E and F) 20 mg/kg of Fc or TOY3 was given intraperitoneally to
the mice at 1 hr and 12 hr after intraperitoneal administration of LPS (15 mg/kg) (E) or at 1 hr and 12 hr after generation of CLP (F). % Survival
represents remaining live mice from total mice (n=10–11).
doi:10.1371/journal.pone.0007403.g006
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Considering that TOY3 has a slightly higher production rate and
smaller molecular size, it will be the most favorable construct for
therapeutic use of TOY in the future. Recently, Roger et al.
reported that a blocking antibody against the N-terminal and
central domains of TLR4 also produced preventive and
therapeutic effects in LPS- and bacteria-induced sepsis models
[26]. Thus, targeting TLR4 either by the blocking antibody or
decoy receptor such as TOY could be an amenable tool to relieve
LPS- and bacteria-induced sepsis [26,27]. In comparison, several
lipid A analogs that are competitive inhibitors of LPS [22,28] are
able to target only LPS-free MD-2, but not LPS-bound MD-2,
whereas TOY could sequester both free and bound forms of MD-
2. Furthermore, since LBP and CD14 play accessory roles in LPS
recognition by TLR4/MD-2 while MD-2 binds to LPS directly
and induces TLR4 dimerization [8,9], the efficacy of targeting
TLR4/MD-2 using TOY could be different from that of blocking
LBP [29] or CD14 [30]. Therefore, the effectiveness of TOY and
blockers of LBP or CD14 should be carefully compared in future
studies. Taken together, TOY would be an effective alternative
therapeutic molecule for treatment of patients with bacterial sepsis,
and our method provides a new platform biotechnology to
generate novel decoy receptor from TLR proteins.
Materials and Methods
Generation of recombinant proteins
Gene constructs encoding different sizes of the ectodomain of
human TLR4 [TFE (amino acid residues 27–631), TOY3 (amino
acid residues 27–227), and TOY8 (amino acid residues 27–527)],
the LRR module of hagfish VLR-B.61 (VLR), and the Fc domain
of human IgG (Fc) were cloned into the pCMV-dhfr vector.
Recombinant Chinese hamster ovary (rCHO) cells expressing
TFE, TOY3, or TOY8 were established following a previously
described method [23]. Briefly, the cells were established by
transfection of a vector containing the dihydrofolate reductase
(dhfr) and TFE, TOY3, or TOY8 gene into dhfr-deficient CHO
cells (CRL-9096, American Type Culture Collection). This was
followed by dhfr/methotrexate (MTX)-mediated gene amplifica-
tion. Stable rCHO cells secreting the highest amount of TFE,
TOY3, or TOY8 were selected with serially-increasing concen-
trations of MTX (0.001–0.08 mM, Sigma-Aldrich). Then the cells
were grown and maintained in HyQ SFM4CHO (Hyclone)
supplemented with 1% dialyzed fetal bovine serum (Invitrogen)
and 0.08 mM MTX. After 4 days, the culture media containing
recombinant proteins were harvested, and the recombinant TFE,
TOY3, or TOY8 proteins were purified by using Protein-A
sepharose affinity chromatography with subsequent acid elution
and neutralization. After purification, each protein was quantitat-
ed using the Bradford assay and confirmed with Coomassie blue
staining of an SDS-PAGE gel.
In vitro binding assay
200 ng of BSA or MD-2 was coated onto 96-well plates. After
blocking with 1% BSA for 1 hr, 40 mg/ml of Fc, TFE, TOY3, or
TOY8 was incubated in each well for another 1 hr with or without
FITC-labeled LPS (10 mg/ml). An HRP-conjugated anti-Fc
antibody was incubated in each well for 1 hr, and then HRP
substrate was added to each well. The fluorescence signal was
measured by IVIS imaging, and the absorbance was measured by
microplate reader (Bio-Rad).
Surface plasmon resonance assay and isoelectric
focusing
Binding between TFE, TOY3, or TOY8 and MD-2 were
analyzed with the BIAcore 3000 (BIAcore AB). One microgram of
TFE, TOY3, or TOY8 was immobilized on a Sensor Chip CM5
(BIAcore) using N-hydroxysuccinimide (NHS) and 1-ethyl-3(3-
dimethylaminopropyl) carbodiimide (EDC) amine coupling re-
agent at approximately 2,000 resonance units (RU). As a control,
BSA protein was immobilized on another portion of the same
chip. Recombinant MD-2 proteins were then applied onto the
immobilized TFE, TOY3, or TOY8 surfaces, and the amount
captured was recorded in sensorgrams as RU. All samples were in
running buffer to minimize bulk effects. The kinetic parameters of
the binding interactions were calculated from the sensorgrams by
nonlinear curve fitting using BIAEVALUATION software
(BIAcore). To measure isoelectric points, 20 mg of each protein
sample and standard marker proteins were loaded on an IsoGel
Agarose IEF Plate pH 3–10 strip (Cambrex) and run at 50 mA
constant current for 3 hr using 1 M phosphoric acid at the anode
and 1 M sodium hydroxide at the cathode. The gels were stained
with Coomassie blue.
Glycosylation analysis of recombinant proteins
Two mg of TFE, TOY3, or TOY8 was incubated with O-
glycosidase or PNGase F (QA-Bio) according to manufacturer’s
Figure 7. TOY ameliorates sepsis in clinically relevant models. (A and B) 20 mg/kg of Fc or TOY3 was given intraperitoneally to mice at 6 hr
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glycosylation pattern was analyzed by the migration shift after
Coomassie blue staining.
In vitro assays for NF-kB and TNF-a
NF-kB activity was assessed by immune-localization of p65 in
nuclei of primary cultured lymphatic endothelial cells according to
methods previously described [31]. Briefly, LEC (primary
lymphatic microvascular endothelial cells derived from human
adult dermis) were purchased from Cambrex Inc. (East Ruther-
ford) and maintained in endothelial cell basal medium-2 with
growth supplements (EBM-2 MV). Passage 4–6 LEC were
incubated in EBM-2 MV containing 1 % FBS for 8 hr and then
with 1 mg/ml of Fc, TFE, TOY3, or TOY8 for 15 min, and then
Figure 8. TOY attenuates LPS-induced NF-kB activation, secretion of proinflammatory cytokines, and thrombus formation. (A and B)
NFkB-RE-luc mice were injected intraperitoneally with control PBS (C) or 20 mg/kg of Fc, TOY3 (T3), or TOY8 (T8) at 1 hr after intraperitoneal
administration of C or LPS (1 mg/kg). At 24 hr later, the luminescence signals from the whole body were examined by IVIS imaging (A). The
luminescence was quantified and expressed as radiance (photon/sec/cm
2/steradian) (B). Bars represent means 6 S.D. (n=3–4). *, P,0.05 versus C+C;
#, P,0.05 versus C+LPS or Fc+LPS. (C and D) Wild-type mice were injected intraperitoneally with C or 20 mg/kg of Fc, T3, or T8 at 1 hr after
intraperitoneal administration of LPS (7.5 mg/kg) or C. At 6 and 24 hr later, plasma levels of TNF-a, IL-1b, and IL-6 were measured (C). Bars represent
means 6 S.D. (n=4–5). *, P,0.05 versus Fc+LPS. At 24 hr after treatment, the mice were anesthetized, and samples of liver, adrenal gland, lung, and
brain were H&E stained (D). Arrows indicate thrombi in the blood vessels. Scale bars, 100 mm.
doi:10.1371/journal.pone.0007403.g008
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cultured macrophages from mouse peritoneal cavity were used to
assay TNF-a secretion. Three days after intraperitoneal injection
of 1 ml of 3% thioglycolate into 9-week-old male C57BL/6 mice,
we harvested macrophages by peritoneal lavage with PBS. We
incubated 1610
6 macrophages per experimental condition in
RPMI 1640 (Lonza) supplemented with 10% dialyzed fetal bovine
serum (Invitrogen). The macrophages were pre-incubated for
30 min with 1 mg/ml of Fc, TOY3, or TOY8, and then treated
with LPS (100 ng/ml) for 4 hr. Culture media were sampled, and
levels of TNF-a were measured by ELISA (R&D systems).
ECM binding assay and pharmacokinetic analysis
ECM-coated 96-well plates (Becton Dickinson) were used for
ECM binding assays. Each recombinant protein (100 mg of Fc,
TOY3, or TOY8) was injected subcutaneously into 8-week-old
male C57BL/6 mice (,25 g body weight), then the amount of
each recombinant protein in blood was measured at the indicated
times by sandwich ELISA.
Animals
Specific pathogen-free 8–9-week-old male C3H/HeN mice and
NFkB-RE-luc [25] (Balb/C) mice were used. Animal care and
experimental procedures were performed under approval from the
Animal Care Committees of KAIST. To generate the LPS-
induced sepsis model, mice were injected intraperitoneally with
15 mg/kg of LPS (E. coli O111:B4; List Biological Laboratories).
To generate the CLP-induced sepsis model, mice were anesthe-
tized, and ,75% of the cecum was ligated and punctured with a
21-gauge needle. The mice received 20 mg/kg of Fc, TOY3, or
TOY8 into the peritoneal cavity prior to or after the generation of
sepsis.
Monitoring NF-kB activation, measurement of
proinflammatory cytokines, and histology
NFkB-RE-luc [25] and wild-type mice were given 1.0 and
7.5 mg/kg of LPS 1 hr prior to administration of 20 mg/kg of Fc,
TOY3, or TOY8. At 24 hrs after the LPS administration, the
luminescence signal was examined by the IVIS imaging system
(Xenogen). Plasma was sampled at 6 and 24 hrs, and levels of
TNF-a, IL-1b, and IL-6 were measured by ELISA (R&D systems).
Mice were sacrificed 24 hours after LPS treatment, and their
livers, adrenal glands, lungs, and brains were harvested for
histological studies. Harvested organs were fixed using 4% PFA
dissolved in PBS at 4uC overnight and embedded in paraffin
blocks. Sections (4-mm) were stained with H&E and analyzed
under a phase-contrast light microscope.
Statistics
Values are presented as means 6 S.D. Significant differences
between means were determined by analysis of variance followed
by the Student-Newman-Keuls test. For analysis of survival curves,
a log-rank test was performed.
Supporting Information
Figure S1 In vitro binding analysis reveals that TFE, TOY3, or
TOY8 could interact not only with MD-2 but also with LPS/MD-
2 complex. (A) BSA or MD-2 was coated onto 96-well plates and
40 mg/ml of Fc, TFE, TOY3, or TOY8 was incubated in each
well with or without FITC-labeled LPS. An HRP-conjugated anti-
Fc antibody was incubated in each well, and then HRP substrate
was added. The fluorescence signal of each well is shown. (B)
Fluorescence and absorbance were measured. Fluorescence is
expressed as radiance (photon/sec/cm2/steradian) on the left y-
axis, and absorbance is shown on the right y-axis. Bars represent
means 6 S.D. (n=4). *, P,0.05 versus hMD-2+Fc (5); #,P ,0.05
versus hMD-2+FITC-LPS+Fc (9). The x-axis numbering repre-
sents the number of each well in (A).
Found at: doi:10.1371/journal.pone.0007403.s001 (1.28 MB TIF)
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